UCB SA (UCBJF)
| Market Cap | 42.36B |
| Revenue (ttm) | 8.04B |
| Net Income (ttm) | 1.56B |
| Shares Out | n/a |
| EPS (ttm) | 8.06 |
| PE Ratio | 27.08 |
| Forward PE | 22.18 |
| Dividend | 1.58 (0.71%) |
| Ex-Dividend Date | Apr 25, 2025 |
| Volume | 11 |
| Average Volume | 2,102 |
| Open | 223.24 |
| Previous Close | 223.09 |
| Day's Range | 223.24 - 223.24 |
| 52-Week Range | 150.70 - 224.64 |
| Beta | 0.24 |
| RSI | 61.78 |
| Earnings Date | Jul 31, 2025 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra... [Read more]
Financial Performance
In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.
Financial numbers in EUR Financial StatementsNews
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Three major pharmaceutical companies — Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Co (NYSE: LLY), and UCB SA (OTC: UCBJY) (OTC: UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) R...
United Community Banks UCB Earnings Transcript
UCB SA (UCBJF) Q2 2025 Earnings Call Transcript
UCB SA 2025 Q2 - Results - Earnings Call Presentation
UCB SA reports 1H results
United Community Banks, Inc. (UCB) Q2 2025 Earnings Call Transcript
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results
UCB SA (OTC: UCBJY) (OTC: UCBJF) (Euronext Brussels: UCB) and Biogen Inc . (NASDAQ: BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizum...
United Community Banks, Inc. (UCB) Q1 2025 Earnings Call Transcript
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders
On Friday, UCB SA (OTC: UCBJY) (OTC: UCBJF) announced further long-term data from the Phase 3 trials and their open-label extensions, investigating Bimzelx (bimekizumab) in adults with moderate-to- ...
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
Over half of patients had no draining tunnels (DTs) at two years: In 425 hidradenitis suppurativa (HS) patients with ≥1 DTs at baseline, 55.7% (195/350) had no DTs at two years of treatment. ≠ DTs are...
UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations Drive Success
Full Year 2024 Ucb SA Earnings Call Transcript
Full Year 2024 Ucb SA Earnings Call Transcript
Decoding United Community Banks Inc (UCB): A Strategic SWOT Insight
Decoding United Community Banks Inc (UCB): A Strategic SWOT Insight
United Community Banks, Inc. (UCB) Q4 2024 Earnings Call Transcript
United Community Banks, Inc. (NYSE:UCB) Q4 2024 Earnings Call January 22, 2025 9:00 AM ETCompany ParticipantsLynn Harton - Chairman and CEOJefferson...
United Community Banks Non-GAAP EPS of $0.63 beats by $0.07, revenue of $239.47M misses by $3.26M
United Community Banks (UCB) reports Q4 Non-GAAP EPS beating expectations by $0.07, but revenue missing by $3.26M, up 44.5% Y/Y.
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
BIMZELX ® (bimekizumab-bkzx) is now commercially available by prescription in the United States in a 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX The single-injection dev...
United Community Banks Inc (UCB) Announces Upcoming Fourth Quarter 2024 Financial Results Release
United Community Banks Inc (UCB) Announces Upcoming Fourth Quarter 2024 Financial Results Release
United Community Banks to acquire ANB Holdings in an all-stock deal
Financial holding company United Community Banks (UCB) is set to acquire ANB Holdings, and the unit American National Bank, in an all-stock transaction.
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
On Tuesday, UCB SA (OTC: UCBJY) (OTC: UCBJF) and Biogen Inc. (NASDAQ: BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ery...
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
On Wednesday, the FDA approved UCB SA’s (OTC: UCBJY) (OTC: UCBJF) Bimzelx (bimekizumab-bkzx) for adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab-bkzx is the first and only ...
UCB gets FDA approval for Bimzelx for hidradenitis suppurativa
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
United Community Banks: Too Rich For My Blood
United Community Banks' balance sheet shows mixed results in deposits and debt. Read more to see why I think UCB stock is a sell.
Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy
UCB SA has a promising drug, Bimzelx, despite temporary EBITDA decline and potential regulatory hurdles ahead. Learn more about UCBJF stock here.
UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
Clinically meaningful improvements observed with BIMZELX over one year of treatment were maintained up to two years (Week 96) At Week 96, over eight in 10 patients treated with BIMZELX achieved HiSCR5...